Catherine Wu

Catherine Wu is a leading pioneer in personalized neoantigen cancer vaccines, developing the NeoVax platform at Dana-Farber Cancer Institute. Her landmark clinical trials demonstrated that patient-specific neoantigen vaccines can elicit robust T cell responses in melanoma and glioblastoma. She has advanced the field of personalized immunotherapy by integrating whole-exome sequencing with neoantigen prediction algorithms. Her work has established the scientific foundation for combining neoantigen vaccines with checkpoint inhibitors.